CRISPR Therapeutics
CRSP
83 hedge funds and large institutions have $293M invested in CRISPR Therapeutics in 2017 Q4 according to their latest regulatory filings, with 35 funds opening new positions, 22 increasing their positions, 10 reducing their positions, and 16 closing their positions.
120% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 10
119% more first-time investments, than exits
New positions opened: 35 | Existing positions closed: 16
107% more call options, than puts
Call options by funds: $3.23M | Put options by funds: $1.56M
63% more capital invested
Capital invested by funds: $180M → $293M (+$114M)
30% more funds holding
Funds holding: 64 → 83 (+19)
5.7% more ownership
Funds ownership: 24.77% → 30.47% (+5.7%)
50% less funds holding in top 10
Funds holding in top 10: 6 → 3 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$16.3M |
| 2 |
BlackRock
New York
|
+$10.4M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$6.89M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$5.34M |
| 5 |
GTC
Ghost Tree Capital
New York
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$6.65M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$2.71M |
| 3 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$2.33M |
| 4 |
HP
Harbourvest Partners
Boston,
Massachusetts
|
-$1.75M |
| 5 |
LCM
Laurion Capital Management
New York
|
-$1.21M |
CRSP Hedge Fund Activity: Q4 2017 in Review
83 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q4 2017, worth a combined $293M — up 63% from $180M a quarter earlier.
Buyers outnumbered sellers: 35 funds opened new CRSP positions and 16 closed out — a net gain of 19 holders — while 22 added to existing stakes and 10 trimmed.
The largest buyer was Farallon Capital Management, opening a new position worth an estimated $16.3M. The largest seller was OrbiMed, exiting entirely with an estimated $6.65M sold.
- 83 institutional investors held CRISPR Therapeutics (CRSP) as of Q4 2017, up from 64 in Q3 2017.
- Funds reported $293M of CRISPR Therapeutics stock for Q4 2017, up 63% quarter-over-quarter.
- 35 funds opened new CRISPR Therapeutics positions in Q4 2017 and 16 closed out, a net change of +19 holders.
- The largest CRISPR Therapeutics buyer in Q4 2017 was Farallon Capital Management, an estimated $16.3M added.
- The largest CRISPR Therapeutics seller in Q4 2017 was OrbiMed, an estimated $6.65M sold.
Based on aggregated 13F filings for Q4 2017.